致所有BI用户的一封信

2021-01-11 11:21

尊敬的各位BI用户：

LETTER TO BI CUSTOMERS

大家好！

Greetings!

2019年12月，德国赛多利斯（Sartorius）与以色列Biological Industries（BI）签署合作协议，收购BI公司多数股权（详情请查看链接：https://www.sartorius.com/en/company/newsroom/corporate-news/370526-370526）。BI中国区业务将进行调整，调整如下：

In Dec. 2019, Sartorius（Germany）and Biological Industries, Israel（BI） had signed an agreement in acquiring major shares of Biological Industries（See link above）. The business structure in China will be adjusted as follows：

1. 血清系列产品

Serum Product Line

BI公司将停止在中国销售其品牌下动物血清系列产品，转交由上海逍鹏生物科技有限公司VivaCell品牌继续销售，保证原有产品质量，并一如既往地承担技术与客户服务业务。

BI will stop all animal serum business in China, all related business will be transferred to Shanghai XP Biomed Ltd.（XP）and operate under VivaCell（VC）brand name. VC will guarantee original product quality and providing same technical support and customer service.

2. 其他系列产品

Other BI business

如：无血清培养基（干细胞、免疫细胞、Vero等）、基础培养基、细胞辅助试剂（胰酶、冻存液、支原体相关试剂）等，将维持原品牌与销售渠道。

Such as Serum Free Medium（NutriStem® series, Immuno cell, Vero etc.）, Basal Medium, Ancillary Materials（Trypsin, freezing solution, mycoplasma related reagents）etc, will remain under same BI brand and sales channel.

逍鹏生物仍为BI在中国区域（含香港、澳门区域）的代理商，代理权限不变（详情查看链接：https://www.bioind.com/worldwide/distributors/），继续负责执行原本工作职能，提供市场推广、知识培训、技术支持及客户售前售后服务。

XP is still BI's agent in China（Including Hong Kong and Macao）, and the agency authority remains unchanged （See link above）.Operated continuously by Shanghai XP Biomed Ltd. XP will carry on its original function, providing marketing promotion, education training, technical support and pre/after sales services.